South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT ID: NCT00121966
Last Updated: 2008-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
400 participants
INTERVENTIONAL
2003-01-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To investigate whether insulin aspart with meals is better than a standard treatment with insulin NPH at bedtime, evaluated by HbA1c.
The secondary objectives of this study are:
* To study if a combination treatment with metformin and/or rosiglitazone and insulin aspart with meals is better than a standard treatment with insulin NPH combined with one or more of the above oral antidiabetic drugs. According to the hypothesis, special focus will be given to the treatment group with insulin aspart combined with metformin and rosiglitazone. The treatment effect will be evaluated by HbA1c.
* To examine the effects of the treatments on glucose metabolism and beta cell function, evaluated by diurnal blood glucose, fasting plasma glucose, insulin, C-peptide, and lactate.
* To examine the effects of the treatments on cardiovascular risk factors evaluated by serum lipid profiles, serum free fatty acids, urine albumin/creatinine ratio, and electrocardiogram (ECG).
* To quantify and describe the patients' subjective experiences of the two different insulin treatments (quality of life assessment)
* To examine patients with type 2 diabetes for the presence of variability in a series of genes, which are known to or are assumed to:
* affect the long term outcome;
* determine the responsiveness to treatment with diet, exercise and drugs targeting the known risk markers for late diabetic complications; and
* after intervention, to analyse the complex interrelationships between genotypes and clinical endpoints and the responsiveness to actual treatment modalities.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin Aspart
Insulin NPH
Metformin
Rosiglitazone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting C-peptide \>300 pmol/l
* Body mass index (BMI) \> 25 kg/m2
* Diabetes for more than 2 years
* Pharmacological antidiabetic treatment for more than 3 months
* 7.0%\<HbA1c\<12.0% at randomisation
* Patient willing to sign informed consent
* Fertile women: negative pregnancy test and use of oral or intra-uterine contraception or depot gestagen.
Exclusion Criteria
* History of intolerance to metformin or glitazones
* S-ALAT/S-ASAT \> 2.5 x upper normal limit
* Total cholesterol \> 10 mmol/l
* Total triglyceride \> 8 mmol/l
* Hemoglobin (Hb) \< normal range
* Treatment with glitazone preceding 30 days New York Heart Association (NYHA) functional class III or IV
* Night work
* Present or planned pregnancy
* Poor vision impeding insulin administration
* Unawareness of hypoglycaemia (complete or partly)
* Mental illness or alcohol abuse
* Clinically relevant major organ or systemic illness
* Uncontrolled hypertension \>180/110 mmHg, systolic or diastolic
* Steroid treatment
* Severe lung disease
* A history of malign disease
* An expectation that the patient will not be collaborative or will not be able to understand the character of this trial
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ribe County Hospital, Esbjerg, Denmark
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeppe Gram, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Esbjerg Hospital - University Hospital of Southern Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diabetes Research Center
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Skov V, Cangemi C, Gram J, Christensen MM, Grodum E, Sorensen D, Argraves WS, Henriksen JE, Rasmussen LM. Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes. Diabetes Care. 2014;37(3):760-6. doi: 10.2337/dc13-1022. Epub 2013 Oct 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001
Identifier Type: -
Identifier Source: org_study_id